5-HydroxytryptamineCAS# 50-67-9 |
Quality Control & MSDS
3D structure
Package In Stock
Number of papers citing our products
| Cas No. | 50-67-9 | SDF | Download SDF |
| PubChem ID | 5202 | Appearance | Powder |
| Formula | C10H12N2O | M.Wt | 176 |
| Type of Compound | N/A | Storage | Desiccate at -20°C |
| Solubility | Soluble in Chloroform,Dichloromethane,Ethyl Acetate,DMSO,Acetone,etc. | ||
| Chemical Name | 3-(2-aminoethyl)-1H-indol-5-ol | ||
| SMILES | C1=CC2=C(C=C1O)C(=CN2)CCN | ||
| Standard InChIKey | QZAYGJVTTNCVMB-UHFFFAOYSA-N | ||
| Standard InChI | InChI=1S/C10H12N2O/c11-4-3-7-6-12-10-2-1-8(13)5-9(7)10/h1-2,5-6,12-13H,3-4,11H2 | ||
| General tips | For obtaining a higher solubility , please warm the tube at 37 ℃ and shake it in the ultrasonic bath for a while.Stock solution can be stored below -20℃ for several months. We recommend that you prepare and use the solution on the same day. However, if the test schedule requires, the stock solutions can be prepared in advance, and the stock solution must be sealed and stored below -20℃. In general, the stock solution can be kept for several months. Before use, we recommend that you leave the vial at room temperature for at least an hour before opening it. |
||
| About Packaging | 1. The packaging of the product may be reversed during transportation, cause the high purity compounds to adhere to the neck or cap of the vial.Take the vail out of its packaging and shake gently until the compounds fall to the bottom of the vial. 2. For liquid products, please centrifuge at 500xg to gather the liquid to the bottom of the vial. 3. Try to avoid loss or contamination during the experiment. |
||
| Shipping Condition | Packaging according to customer requirements(5mg, 10mg, 20mg and more). Ship via FedEx, DHL, UPS, EMS or other couriers with RT, or blue ice upon request. | ||
5-Hydroxytryptamine Dilution Calculator
5-Hydroxytryptamine Molarity Calculator
| 1 mg | 5 mg | 10 mg | 20 mg | 25 mg | |
| 1 mM | 5.6818 mL | 28.4091 mL | 56.8182 mL | 113.6364 mL | 142.0455 mL |
| 5 mM | 1.1364 mL | 5.6818 mL | 11.3636 mL | 22.7273 mL | 28.4091 mL |
| 10 mM | 0.5682 mL | 2.8409 mL | 5.6818 mL | 11.3636 mL | 14.2045 mL |
| 50 mM | 0.1136 mL | 0.5682 mL | 1.1364 mL | 2.2727 mL | 2.8409 mL |
| 100 mM | 0.0568 mL | 0.2841 mL | 0.5682 mL | 1.1364 mL | 1.4205 mL |
| * Note: If you are in the process of experiment, it's necessary to make the dilution ratios of the samples. The dilution data above is only for reference. Normally, it's can get a better solubility within lower of Concentrations. | |||||
Calcutta University
University of Minnesota
University of Maryland School of Medicine
University of Illinois at Chicago
The Ohio State University
University of Zurich
Harvard University
Colorado State University
Auburn University
Yale University
Worcester Polytechnic Institute
Washington State University
Stanford University
University of Leipzig
Universidade da Beira Interior
The Institute of Cancer Research
Heidelberg University
University of Amsterdam
University of Auckland
TsingHua University
The University of Michigan
Miami University
DRURY University
Jilin University
Fudan University
Wuhan University
Sun Yat-sen University
Universite de Paris
Deemed University
Auckland University
The University of Tokyo
Korea University
- Niclosamide
Catalog No.:BCC5081
CAS No.:50-65-7
- Chloroquine diphosphate
Catalog No.:BCC3915
CAS No.:50-63-5
- Oxytocin
Catalog No.:BCC5435
CAS No.:50-56-6
- Reserpine
Catalog No.:BCN4960
CAS No.:50-55-5
- Estradiol Benzoate
Catalog No.:BCC4779
CAS No.:50-50-0
- Mercaptopurine (6-MP)
Catalog No.:BCC1186
CAS No.:50-44-2
- Clomiphene citrate
Catalog No.:BCC4480
CAS No.:50-41-9
- Cocaine
Catalog No.:BCN1901
CAS No.:50-36-2
- Thalidomide
Catalog No.:BCC2248
CAS No.:50-35-1
- Phenylbutazone
Catalog No.:BCC4822
CAS No.:50-33-9
- beta-Estradiol
Catalog No.:BCN2194
CAS No.:50-28-2
- Estriol
Catalog No.:BCN2235
CAS No.:50-27-1
- 1,3:2,4-Di-p-methylbenyliedene sorbitol
Catalog No.:BCC4847
CAS No.:54686-97-4
- Actinomycin D
Catalog No.:BCC2385
CAS No.:50-76-0
- Aspirin (Acetylsalicylic acid)
Catalog No.:BCC2097
CAS No.:50-78-2
- Ascorbic acid
Catalog No.:BCN2207
CAS No.:50-81-7
- Thymidine
Catalog No.:BCN5622
CAS No.:50-89-5
- Floxuridine
Catalog No.:BCC1187
CAS No.:50-91-9
- Ephedrine Hydrochloride
Catalog No.:BCC8322
CAS No.:50-98-6
- D-(+)-Glucose
Catalog No.:BCN1259
CAS No.:50-99-7
- Nordihydroguaiaretic acid
Catalog No.:BCC1805
CAS No.:500-38-9
- L-Mimosine
Catalog No.:BCC5450
CAS No.:500-44-7
- Apoatropine
Catalog No.:BCN1869
CAS No.:500-55-0
- Convolamine
Catalog No.:BCN1905
CAS No.:500-56-1
Chrysin ameliorates ANTU-induced pulmonary edema and pulmonary arterial hypertension via modulation of VEGF and eNOs.[Pubmed:30974023]
J Biochem Mol Toxicol. 2019 Apr 11:e22332.
Alpha-naphthylthiourea (ANTU), a rodenticide induces lung toxicity. Chrysin a flavonoid possesses antioxidant, anti-inflammatory, and antihypertensive potential. The aim of this study was to evaluate the efficacy of chrysin against ANTU-induced pulmonary edema (PE) and pulmonary arterial hypertension (PAH) in laboratory rats. Sprague-Dawley rats were used to induce PE (ANTU, 10 mg/kg, ip) and PAH (ANTU, 5 mg/kg, ip, 4 weeks). Animals were treated with chrysin (10, 20, and 40 mg/kg) and various biochemical, molecular, and histological parameters were evaluated. Acute administration of ANTU induces PE revealed by significant (P < 0.05) increase in relative lung weight, pleural effusion volume, lung edema, bronchoalveolar lavage fluid cell counts, total protein, 5-Hydroxytryptamine (5-HT), lactate dehydrogenase (LDH), and gamma-glutamyl transferase (GGT), whereas pretreatment with chrysin (20 and 40 mg/kg, ip) significantly (P < 0.05) attenuated these ANTU-induced biochemical and histological alterations. Repeated administration of ANTU caused induction of PAH evaluated by significant (P < 0.05) alterations in electrocardiographic, hemodynamic changes, and left ventricular function, whereas chrysin (20 and 40 mg/kg, p.o.) treatment significantly (P < 0.05) attenuated these alterations. ANTU-induced hematological and serum biochemical (aspartate transaminase, alanine transaminase, LDH, and creatinine kinase MB) alterations were significantly (P < 0.05) inhibited by chrysin. It also significantly (P < 0.05) decreased elevated levels of oxido-nitrosative stress in the right ventricle (RV) and lung. Chrysin significantly (P < 0.05) attenuated downregulated endothelial nitric oxide synthase and upregulated vascular endothelial growth factor messenger RNA and protein expressions both in the RV and pulmonary artery. Chrysin inhibited ANTU-induced PE and PAH via modulation of inflammatory responses (5-HT, LDH, and GGT), oxido-nitrosative stress, and VEGF and eNOs levels.
